Clinuvel Pharmaceuticals (ASX:CUV) Other Current Receivables: A$0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:CUV Clinuvel Pharmaceuticals Ltd ASX:CUV
81 GF Score
Price A$10.19
GF Value A$17.77
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Clinuvel Pharmaceuticals Other Current Receivables?

Clinuvel Pharmaceuticals ASX:CUV -0.29% 81 Other Current Receivables is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:CUV with a GF Score™ of 81/100 and a GF Value™ of A$17.77 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Clinuvel Pharmaceuticals's Other Current Receivables for the quarter that ended in Dec. 2025 was A$0.00 Mil.

Clinuvel Pharmaceuticals's annual Other Current Receivables declined from Jun. 2023 (A$1.41 Mil) to Jun. 2024 (A$1.08 Mil) but then increased from Jun. 2024 (A$1.08 Mil) to Jun. 2025 (A$3.14 Mil).

Clinuvel Pharmaceuticals Other Current Receivables Related Terms

Clinuvel Pharmaceuticals Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Clinuvel Pharmaceuticals's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clinuvel Pharmaceuticals Other Current Receivables Chart

Clinuvel Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.28 0.30 1.41 1.08 3.14

Clinuvel Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 1.08 0.00 3.14 0.00
ASX:CUV
81GF Score
Clinuvel Pharmaceuticals Ltd ASX:CUV
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clinuvel Pharmaceuticals Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of A$0.00 Mil mean?
Clinuvel Pharmaceuticals (ASX:CUV) has a Other Current Receivables of A$0.00 Mil as of Dec. 2025. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Clinuvel Pharmaceuticals and its competitors.
Is Clinuvel Pharmaceuticals' Other Current Receivables too high?
Clinuvel Pharmaceuticals' current Other Current Receivables is A$0.00 Mil. Overall, Clinuvel Pharmaceuticals has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Clinuvel Pharmaceuticals' Other Current Receivables compare to VRTX and REGN?
Clinuvel Pharmaceuticals' Other Current Receivables of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Clinuvel Pharmaceuticals and its competitors. Clinuvel Pharmaceuticals's current Other Current Receivables is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinuvel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals (ASX:CUV) is currently considered Significantly Undervalued. The stock's GF Value™ is A$17.77, compared to a current price of A$10.19 — trading 42.7% below its estimated fair value. The current Other Current Receivables is A$0.00 Mil. Clinuvel Pharmaceuticals' overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Clinuvel Pharmaceuticals (ASX:CUV), the current Other Current Receivables is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Clinuvel Pharmaceuticals (ASX:CUV) Overvalued in 2026?

Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued. The current stock price of A$10.19 is trading 42.7% below its estimated GF Value™ of A$17.77. GuruFocus considers Clinuvel Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for ASX:CUV:

  • Other Current Receivables: A$0.00 Mil
  • GF Value™: A$17.77 vs. price of A$10.19 (42.7% below fair value)
  • GF Score™: 81/100 with 2 warning signs

No single metric tells the full story. See the ASX:CUV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Clinuvel Pharmaceuticals Business Description

Address 535 Bourke Street, Level 22, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
81GF Score

Get the complete analysis for ASX:CUV

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$10.19
Price
A$17.77
GF Value